Nigeria pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
Dosing
Page 30 of 31 of this archive, newest first.
The site you keep using is the site that stops working
Repeated injection into the same small area produces lipohypertrophy — thickened, rubbery subcutaneous tissue with blunted and erratic absorption. It is common, it is…
A supply gap is a pharmacological event
One omitted dose is a labelling question. Four omitted doses is a clinical one. The two are routinely conflated.
Severity grading, and the gap between a grade and an experience
Trial adverse-event tables count episodes reported to a study nurse. They are the best data we have and they systematically under-record the mundane.
What the new New Zealand guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
What the cagrilintide schedule assumes about a person it has never met
The four-week step exists because four to five weeks is approximately how long a once-weekly drug takes to stop rising at a fixed dose. That is a good reason, and it is not…
What the new Canada guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Escalating past the approved maximum, examined honestly
Where the curve flattens, what flattens with it, and what does not.
Side effects, cost, supply, target: four reasons with four trajectories
Real-world persistence figures, with their definitions stated, because the definitions are doing most of the work.
What SURPASS-3 tells us about maintenance, and what it does not
What the labels permit, what clinicians do, and the size of the gap between them.
Nigeria pharmacy body issues counselling standards for liraglutide initiation
The evidence base is thin and the document says so, which is to its credit.
What the new India guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Background rates, and why they matter for attribution
Rapid weight loss by any means raises gallstone risk. Separating that from a direct drug effect requires a comparator, and the trials have one.
The escalation table is the thinnest page in the label
The published ladder exists because a protocol needed a single number. Practice has never followed it exactly, and the regulatory file never assumed it would.
Units, millilitres, milligrams: three scales on one small object
A unit is a volume. A dose is a mass. The bridge between them is concentration, and concentration is a number somebody has to calculate.
What the new France guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Why receptor selectivity is the least discussed number in incretin pharmacology
Selectivity, potency and efficacy are three different measurements. The trade routinely reports none of them.
What the new Turkey guidance says about stopping
The evidence base is thin and the document says so, which is to its credit.
Dose-limiting: a definition worth being strict about
Roughly four to seven per cent of trial participants discontinued for adverse events, mostly gastrointestinal, mostly during escalation. That is the empirical size of the…
Albumin, fatty-acid chains, and the engineering that made a weekly incretin possible
The molecular engineering that turned a peptide with a two-minute half-life into a once-weekly drug.